CRISPR Technology Market

Vertex sold USD 99 million of Casgevy, the first approved CRISPR medicine, in the third quarter of 2026, nearly six times the USD 17 million of a year earlier, its results of 2 November 2026 show, and three days later Intellia said the US Food and Drug Administration (FDA) had accepted its lonvo-z gene editing filing with a decision date of 10 March 2027, its third-quarter release of 5 November 2026 states. The CRISPR technology market covers products and services built on CRISPR gene editing: Cas enzymes, guide RNAs, kits and screening libraries; cell line, animal model and screening services; approved CRISPR-based medicines; and agricultural and other licensing income. Gene editing with zinc fingers or TALENs, generic sequencing and research grants are excluded. Douglas Insights sizes the market at USD 2.20 billion in 2025, about 46,000 paying accounts at an average USD 47,800, and at USD 9.76 billion in 2035, a 16.1% compound annual growth rate (CAGR). The study sits beside our Synthetic Biology Market, Cell and Gene Therapy CDMO Services Market and Protein Engineering Market reports; every figure follows the Douglas Insights research methodology.

Which CRISPR offerings earn the most: research products, editing services, therapeutics or agricultural licensing?

CRISPR research products earn the most, 60.0% of 2025 value or USD 1.32 billion, Douglas Insights estimates. Editing services take 29.1%, agricultural and other licensing 5.6% and approved CRISPR therapeutics 5.3%.

Research products lead because almost every molecular biology laboratory now edits genes, and each experiment consumes a Cas protein or mRNA, synthetic guide RNAs and delivery reagents. Suppliers keep adding tools: Integrated DNA Technologies (IDT), part of Danaher, launched an Alt-R HDR Enhancer Protein made by Aldevron and claims up to twice the rate of precise edits in stem cells, its release of 25 September 2025 states, and Revvity launched AI-designed adenine deaminases with Profluent for its Pin-point base editing system on 22 September 2025, its release shows. Research products grow 8.0% a year to USD 2.85 billion by 2035, a Douglas Insights estimate.

Editing services, USD 640 million, grow 9.0% as drug makers outsource knock-out cell lines, engineered animal models and genome-wide screens. GenScript’s Life Science Group, which sells gene synthesis and editing services, grew 2025 revenue 14.8% to USD 522.1 million, its results of 16 March 2026 show. Service demand also has casualties: Synthego, a synthetic guide RNA and engineered cell supplier, filed for Chapter 11 on 5 May 2025 to sell itself to its lender, its statement says.

Therapeutics are small today but grow fastest, at 45.5% a year to USD 4.93 billion, a Douglas Insights estimate. Casgevy earned USD 115.8 million in 2025, its whole contribution, Vertex’s full-year release of 12 February 2026 shows; the third-quarter 2026 run rate is already above USD 390 million a year, and lonvo-z could launch in early 2027. Agricultural licensing, USD 124 million, grows 14.0%. Offering values for 2035 sum to USD 9.76 billion, 0.07% below the headline.

Who buys CRISPR technology: academic labs, drug developers, treatment centres or seed companies?

Drug and biotech developers buy about 52% of 2025 value, Douglas Insights estimates, academic and government laboratories about 33%, hospital treatment centres about 5% and agricultural and industrial users about 10%.

Drug developers lead because they use CRISPR at every stage: target validation screens, engineered cell lines for assays, and edited cell therapies. Douglas Insights estimates that a large pharmaceutical company spends USD 2 million to USD 10 million a year on CRISPR reagents and services, against USD 5,000 to USD 30,000 for a typical academic laboratory. The 46,000 paying accounts in our model are mostly academic groups by number but drug developers by value.

Academic demand depends on public funding. The US National Institutes of Health (NIH) has about USD 47.5 billion for fiscal 2026, and a court blocked its 15% cap on indirect research costs, with the appeals court upholding that on 5 January 2026, the Congressional Research Service note of 17 April 2026 explains. Treatment centres are the newest buyers: Vertex has activated more than 75 authorised treatment centres in the US, its release of 1 July 2026 states, and each one pays for the edited cells of every patient it infuses. Seed and food companies make up the last group, led by Corteva, Pairwise and Japanese breeders.

What drives CRISPR demand: new approvals, personalised editing, drug discovery screens or new crop rules?

Paying accounts rise 6.00% a year in our base case, from about 46,000 in 2025 to 82,400 in 2035, while spending per account rises 9.50%. Four drivers add 7.00 gross points to account growth; restraints remove 1.00.

Approvals and label expansions: 2.40 points

Medicine approvals are the largest driver, worth 2.40 points. The FDA widened Casgevy to patients aged 2 and older with sickle cell disease or beta thalassemia on 1 July 2026, adding about 5,500 eligible US children, the Vertex release states, and the UK Medicines and Healthcare products Regulatory Agency (MHRA) cleared it for children from age 5 on 29 October 2026, its notice of 30 October 2026 says. Intellia’s phase 3 HAELO trial cut hereditary angioedema attacks by 87% with lonvo-z, and 62% of treated patients were attack-free without other therapy, its release of 27 April 2026 shows. Every approval adds treatment centres and lifts reagent and quality-testing demand upstream.

Personalised editing and new FDA pathways: 1.20 points

Bespoke medicines add 1.20 points. Doctors at Children’s Hospital of Philadelphia and Penn gave an infant with CPS1 deficiency the first personalised base-editing therapy about six months after diagnosis, the NIH announcement of 15 May 2025 states, and the FDA proposed a “plausible mechanism” framework letting one application cover several variants of the same gene, its release of 23 February 2026 shows. Douglas Insights estimates that each bespoke programme buys USD 0.5 million to USD 1 million of guide RNA, editor mRNA and off-target testing.

In vivo programmes and drug discovery screens: 2.00 points

Industrial research adds 2.00 points. CRISPR Therapeutics’ CTX310 lowered triglycerides 55% and LDL cholesterol 49% at its top dose in a 15-patient trial, its release of 8 November 2025 states, and Eli Lilly agreed to buy Verve Therapeutics for up to about USD 1.3 billion including a contingent value right, Verve’s filing of 17 June 2025 shows. Large drug makers entering in vivo editing run many more screening and cell engineering projects, which raises the account count.

New genomic technique rules for crops: 1.40 points

Agriculture adds the last 1.40 points. The EU Council and Parliament agreed on 4 December 2025 to treat category 1 gene-edited plants like conventional ones, labelling only the seeds, the Council release states. Summed, 2.40 + 1.20 + 2.00 + 1.40 = 7.00 points; after 1.00 point of restraints the 6.00% account leg combined with the 9.50% spend leg gives the 16.1% revenue rate.

What holds back CRISPR adoption: safety signals, research funding or cash-strapped developers?

Three restraints remove 1.00 point a year from account growth: safety events take 0.40 points, uncertain academic funding 0.35 points and weak balance sheets among smaller developers 0.25 points.

Safety is the main brake. Intellia paused its MAGNITUDE trials of nex-z on 27 October 2025 after a patient developed grade 4 liver enzyme rises, and the FDA placed both studies on clinical hold on 29 October 2025, its filing states; the patient later died and the holds were lifted in 2026 with extra liver monitoring. The FDA also issued draft guidance on 14 April 2026 asking developers to use next-generation sequencing to assess off-target edits, its release shows, which adds cost but also lifts demand for testing services.

Funding is the second brake. The White House’s fiscal 2027 request proposes the 15% NIH indirect-cost cap again, the Congressional Research Service notes, and Danaher’s Life Sciences sales were flat in 2025 with core revenue down 1.5%, its results of 28 January 2026 show. Developer cash is the third: Prime Medicine held USD 108.8 million at 30 June 2026, down from USD 191.4 million at the end of 2025, its results of 6 August 2026 show, and Caribou said its pivotal ANTLER-3 study is not yet fully funded, its results of 13 August 2026 state.

Which region spends the most on CRISPR technology, and where does spending grow fastest?

North America spends the most, about USD 968 million or 44.0% of 2025 value, led by the United States. The Middle East and Africa grow fastest, at 18.0% a year, as Gulf states treat sickle cell patients.

North America leads because it holds most CRISPR developers, the largest NIH-funded academic base and the biggest Casgevy market. Thermo Fisher’s Life Sciences Solutions segment, which includes its gene editing reagents, earned USD 10.4 billion in 2025, its results of 29 January 2026 show. US spending grows 16.5% as Casgevy reaches younger patients and lonvo-z launches.

Asia Pacific, USD 550 million, grows 16.5% on Chinese research volume and contract services; GenScript’s 2025 revenue grew 61.4% to USD 959.5 million, its results show. China has not yet approved a gene-edited medicine, a Douglas Insights reading of public trial registers. Europe, USD 528 million, grows 15.0%, helped by the crop rule deal and UK paediatric approval. The Middle East and Africa gain from Bahrain’s and the UAE’s paediatric approvals in October 2026, the Vertex release states. Regional values sum to USD 2.55 billion in 2026, 0.03% above the headline, and USD 9.81 billion in 2035, 0.51% above it.

Which companies lead CRISPR technology, from reagent suppliers to editing developers?

Thermo Fisher leads with about 14% of 2025 value, a Douglas Insights estimate, ahead of Merck KGaA’s life science arm at about 11% and IDT at about 10%. The top three hold about 35%.

Merck KGaA’s Life Science sales were EUR 8.98 billion in 2025, up 4.0% organically, with Process Solutions up 10.7%, its results of 5 March 2026 show; its Science and Lab Solutions unit, which sells CRISPR reagents, grew 0.3%. CRISPR Therapeutics, Vertex’s Casgevy partner, held USD 2.28 billion of cash at 30 September 2026 and said more than 750 patients have started Casgevy treatment worldwide, its third-quarter release shows.

The developer tier is next. Beam Therapeutics held USD 1.15 billion of cash at 30 June 2026 and plans a filing for risto-cel as early as the end of 2026, its results of 4 August 2026 show. Editas earned USD 40.5 million of 2025 revenue and holds exclusive human-medicine licences to the Broad Institute’s Cas9 and Cas12a patents, its results of 9 March 2026 show. Intellia, Prime Medicine, Caribou, Takara Bio, Agilent and Lonza share most of the remaining value.

What does CRISPR cost, from a guide RNA to an edited-cell treatment?

A paying account spends an average USD 47,800 in 2025, Douglas Insights estimates; an academic laboratory spends far less, while Casgevy earned Vertex about USD 1.81 million per infused patient.

The treatment figure comes from Vertex’s own numbers: USD 115.8 million of 2025 Casgevy revenue against 64 patients infused, the full-year release shows, a Douglas Insights calculation. That single price explains why therapeutics, at 5.3% of value, already rival the research spending of thousands of laboratories. Research consumables are cheaper per unit: Douglas Insights estimates a chemically modified synthetic guide RNA at USD 100 to USD 300 per sequence in research quantities, a vial of Cas9 protein at a few hundred dollars and a genome-wide knock-out library at USD 5,000 to USD 20,000.

The 9.50% spend leg combines two forces. Mix shift toward edited medicines, which earn thousands of times more per account than reagents, adds about 11 points a year; price competition from Chinese and Indian guide RNA makers and from in-house synthesis takes about 1.5 points back, a Douglas Insights estimate. Average spending per account reaches about USD 52,300 in 2026 and USD 118,000 in 2035. Reagent prices themselves fall about 2% a year, our estimate.

Which rules govern CRISPR technology: FDA guidance, patents and crop regulation?

Three layers govern the market: medicine regulators such as the FDA and MHRA that approve edited therapies, patent rulings that decide who collects CRISPR-Cas9 royalties, and EU and US crop rules on edited plants.

Medicine rules are loosening for rare diseases and tightening on safety evidence. The FDA’s February 2026 plausible mechanism draft and its April 2026 off-target sequencing draft, cited above, set the evidence that developers must buy, and Casgevy’s 1 July 2026 paediatric expansion used a Commissioner’s National Priority Voucher, the Vertex release states. Douglas Insights estimates that off-target sequencing adds USD 1 million to USD 3 million to a typical editing programme before approval.

Patents decide licensing income. The Federal Circuit sent the University of California and Broad Institute dispute over single-guide CRISPR-Cas9 in eukaryotic cells back to the patent board on 12 May 2025, and the board again found for Broad on 26 March 2026, Morrison Foerster explained on 7 April 2026. For crops, the US Department of Agriculture asked for comments by 15 June 2026 on how it should review modified organisms after a court vacated its 2020 rule, the Federal Register notice of 15 May 2026 shows, while the EU deal of December 2025 will apply about two years after publication.

What if approvals stall or edited medicines scale faster: how large is the CRISPR technology market in 2035?

The CRISPR technology market ends 2035 between USD 5.83 billion and USD 14.1 billion across three cases, around a USD 9.76 billion base. The number of approved edited medicines sets most of the spread.

In the slower case another serious safety event slows in vivo programmes, NIH cuts reach laboratories and only Casgevy and lonvo-z sell widely, taking 2.0 points off accounts and 3.5 points off spend. In the faster case base and prime editors win approvals for alpha-1 antitrypsin deficiency and cholesterol disorders, and personalised editing becomes routine for rare diseases, adding 1.5 points to accounts and 2.5 points to spend. One extra point of yearly revenue growth adds about USD 800 million to 2035 value, Douglas Insights estimates.

Company signals bracket the base. Vertex guides 2026 revenue from Casgevy and its pain drug Journavx together at USD 500 million or more, its February 2026 release shows, and Intellia plans a lonvo-z launch in the first quarter of 2027; tool suppliers grew in low single digits in 2025, Thermo Fisher by 4% and Danaher by 3.0%, so the gap between our 16.1% rate and their pace is almost all therapeutics.

Douglas Exclusive: the Edited Patient Pipeline Gauge

The Edited Patient Pipeline Gauge is a Douglas Insights model built from 9 inputs: 4 company results, 3 regulatory decisions, 1 clinical trial readout and 1 NIH case report. It tracks how fast patients reach an edited-cell infusion.

The finding, a Douglas Insights estimate: in 2025 only about 44% of patients who had cells collected for Casgevy were infused within the year, 64 of 147, because manufacturing and conditioning take months; by mid-2026 the gauge shows that ratio rising toward 60% as treatment centres gain experience. The bottleneck in CRISPR medicine is not demand but the time from collection to infusion.

The gauge changes how to read 2027. If lonvo-z, an in vivo therapy given as a single infusion with no cell collection, is approved in March 2027, Douglas Insights expects it to reach more patients in its first year than Casgevy did in its first two, which is why our therapeutic segment grows faster after 2027.

How does the methodology turn 46,000 paying accounts into USD 2.20 billion?

Our methodology multiplies about 46,000 paying CRISPR accounts in 2025 by an average USD 47,800 of spending to reach USD 2.20 billion, then grows accounts 6.00% and spending per account 9.50% a year.

The model covers 4 offerings, 4 buyer groups and 5 regions, using 46 data points, 18 sourced and 28 modelled. Accounts are counted as laboratories, companies, treatment centres and seed breeders that pay for CRISPR products, services or medicines in a year; Casgevy revenue is taken from Vertex filings, and the other splits are Douglas Insights estimates. Arithmetic: 46,000 x USD 47,800 = USD 2.20 billion; USD 2.20 billion x (1.0600 x 1.0950)^10 = USD 9.76 billion. Accounts reach about 48,800 in 2026 and 82,400 in 2035.

Two cross-checks agree. First, the four offerings sum to USD 2.20 billion: USD 1.32 billion of products, USD 640 million of services, USD 116 million of medicines and USD 124 million of licensing. Second, our estimated 35% top-three share implies about USD 770 million of CRISPR revenue for Thermo Fisher, Merck KGaA and IDT, under 3% of their combined life science sales, consistent with a specialist product line. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. Vertex Vertex reports third quarter 2026 financial results (2026)
2. Vertex Vertex fourth quarter and full year 2025 results (2026)
3. Vertex FDA approval of expanded use of Casgevy (2026)
4. MHRA MHRA approves gene editing treatment for children aged five and over (2026)
5. CRISPR Therapeutics (SEC) CRISPR Therapeutics third quarter 2026 results (2026)
6. CRISPR Therapeutics CTX310 phase 1 clinical data (2025)
7. Intellia (SEC) Intellia third quarter 2026 results (2026)
8. Intellia HAELO phase 3 results (2026)
9. Intellia (SEC) Intellia Form 8-K on MAGNITUDE dosing pause (2025)
10. NIH Infant with rare disease first to receive personalized gene editing (2025)
11. US FDA FDA plausible mechanism framework (2026)
12. US FDA FDA draft guidance on genome editing safety (2026)
13. Verve (SEC) Verve Therapeutics Form 8-K, Lilly agreement (2025)
14. Beam (SEC) Beam Therapeutics second quarter 2026 results (2026)
15. Editas (SEC) Editas Medicine full year 2025 results (2026)
16. Thermo Fisher (SEC) Thermo Fisher fourth quarter 2025 results (2026)
17. Merck KGaA Merck KGaA Q4 2025 results (2026)
18. GenScript GenScript 2025 results (2026)
19. Congressional Research Service NIH indirect cost rates (2026)
20. Council of the EU New genomic techniques: Council and Parliament strike deal (2025)
21. Federal Register USDA request for information on modified organisms (2026)

What counts in the CRISPR technology study, and what is excluded?

The study counts CRISPR research products, CRISPR editing services, approved CRISPR-based medicines and CRISPR licensing income, including base and prime editors built on Cas proteins. Zinc finger and TALEN editing, generic reagents, sequencing instruments and research grants are excluded.

The study splits value by 4 offerings, 4 buyer groups and 5 regions: North America, Asia Pacific, Europe, the Middle East and Africa and Latin America. Values are in US dollars at 2025 average exchange rates, counted at the price the buyer pays the supplier or, for medicines, the net revenue the maker reports. Readers following engineered biology can compare our Synthetic Biology Market study.